This web site uses cookies. Do you accept the use of external cookies? Yes No Know more x
Survey about achondroplasia
We have designed a questionnaire with the purpose to better know the population connected to achondroplasia.
The questionnaire is optional and anonymous. The data obtained will be used for statistical purposes and to better understand the natural history of achondroplasia. Please consider answering.
If you would like to take the survey later, you can click on the link at the top "Register at BA"
Go to the survey Not now No, thanks

New cohort revealed for phase 2 of BMN-111

The clinical trial: "A Phase 2 Study of BMN 111 to Evaluate Safety, Tolerability, and Efficacy in Children With Achondroplasia (ACH)"  will have a new cohort of up to  60mg/kg.  This information was obtain in the clinicaltrial.gov page.


Cohort 4 has recently begun with a 30mg/kg/subcutaneous injection daily. And now, a cohort 5 is planned too.


BMN-111 Phase 2


Estimated Primary Completion Date:December 2018 (Final data collection date for primary outcome measure)


Estimated Study Completion Date:  January 2019


Experimental: BMN 111 - Subcutaneous Injection,  open-label sequential cohort dose-escalation study. BMN 111 will be administered as a morning dose in one of the following daily dosing regimens:


  • Cohort 1: 2.5 microgram/kg;
  • Cohort 2: 7.5 microgram/kg;
  • Cohort 3: 15.0 microgram/kg;
  • Cohort 4: 30.0 microgram/kg;
  • Cohort 5: up to 60.0 microgram/kg.

Phase 3 will probably start in the first trimester of 2016. The inclusion and exclusion criteria for phase 3 have not been revealed yet.

To view this site you need Internet Explorer 8 (or a higher version)
or another internet browser.

Thank You.